Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209738 | 0.80 | CRHR1 (0.43) | CASRCRHR1 | |
| SCHEMBL3214523 | 0.77 | CRHR1 (0.62) | CASRCRHR1 | |
| SCHEMBL3210842 | 0.72 | CRHR1 (0.46) | CASRCRHR1 | |
| SCHEMBL3747677 | 0.67 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL2085742 | 0.66 | CRHR1 (0.56) | CASRCRHR1 | |
| SCHEMBL3809137 | 0.66 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL2085121 | 0.65 | CRHR1 (0.49) | CASRCRHR1 | |
| SCHEMBL3212465 | 0.65 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL3724191 | 0.64 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL3285073 | 0.63 | CRHR1 (0.42) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | HRH4, SSTR5, CNR1 | CASR 524/4885CRHR1 4/4885TOP2A 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.